Phase II trial of chlorozotocin in malignant melanoma, breast cancer, and other solid tumors.

Abstract

We have conducted a broad phase II clinical trial of chlorozotocin in 74 patients including 28 with malignant melanoma, 18 with breast cancer, nine with non-Hodgkin's lymphoma, six with nonseminomatous testicular cancer, five with ovarian cancer, four with sarcoma, three with non-beta islet cell carcinoma of the pancreas, and one with anaplastic carcinoma of the thyroid. Objective responses were noted only in 15% of the patients with melanoma and in 11% of the patients with non-Hodgkin's lymphoma. Significant leukopenia and thrombocytopenia were observed only in previously treated patients. Chlorozotocin does not appear to offer clinically significant advantages over other currently available nitrosoureas.

• Authors: B A Silver, A L Barlock, M E Lippman, T Anderson, R I Fisher
• Journal: Cancer treatment reports (Cancer Treat Rep) Vol. 66 Issue 5 Pg. 1229-30 (May 1982) ISSN: 0361-5960 [Print] United States
• PMID: 6211231 (Publication Type: Journal Article)

Chemical References

• Antineoplastic Agents
• chlorozotocin
• Streptozocin

Topics

• Adolescent
• Adult
• Aged
• Antineoplastic Agents (therapeutic use)
• Breast Neoplasms (drug therapy)
• Drug Evaluation
• Female
• Humans
• Male
• Melanoma (drug therapy)
• Middle Aged
• Neoplasms (drug therapy)
• Streptozocin (analogs & derivatives, therapeutic use, toxicity)